A meta-analysis of nearly 23K patients receiving immune checkpoint inhibitors for any malignancy demonstrates experiencing any of a wide array of cutaneous reactions was associated with improved progression free (HR 0.52) and even overall (HR 0.61) survival. | Du, JAMA Dermatol 2023
